drugset / Trial / NCT00170755

A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder

NCT00170755

Phase 3 Completed 718 enrolled Novartis
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will evaluate the safety, tolerability and efficacy of darifenacin, in the long-term treatment of adult patients with overactive bladder.

Timeline

Start
2002-04
Primary completion
Completion
2005-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Darifenacin Small molecule 7.5 mg Oral
Subject Darifenacin Small molecule 15 mg Oral

Indications